AHR - aryl hydrocarbon receptor Gene

Also Known as RP85; bHLHe76

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 196

About AHR

Cytogenetic location: 7p21.1 Genomic coordinates (GRCh38): 7:17,298,652-17,346,147 (from NCBI)

This gene has 7 transcripts (splice variants), 151 orthologues, 1 paralogue and is associated with 3 phenotypes. Ubiquitous expression in urinary bladder (RPKM 37.2), gall bladder (RPKM 28.4) and 24 other tissues.

Summary

The protein encoded by this gene is a ligand-activated helix-loop-helix transcription factor involved in the regulation of biological responses to planar aromatic hydrocarbons. This receptor has been shown to regulate xenobiotic-metabolizing Enzymes such as Cytochrome P450. Before ligand binding, the encoded protein is sequestered in the cytoplasm; upon ligand binding, this protein moves to the nucleus and stimulates transcription of target genes. [provided by RefSeq, Sep 2015]

AHR Products (1)

mRNA Protein Name
NM_001621.5 NP_001612.1 aryl hydrocarbon receptor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables DNA binding IDA
IDA: Inferred from direct assay
15681594 GOA
enables DNA-binding transcription factor activity IDA
IDA: Inferred from direct assay
11782478 GOA
enables Hsp90 protein binding IDA
IDA: Inferred from direct assay
9079689 GOA
enables RNA polymerase II-specific DNA-binding transcription factor binding IPI
IPI: Inferred from physical interaction
9079689 GOA
enables TBP-class protein binding IPI
IPI: Inferred from physical interaction
15641800 GOA
enables TFIID-class transcription factor complex binding IPI
IPI: Inferred from physical interaction
15641800 GOA
enables cis-regulatory region sequence-specific DNA binding IDA
IDA: Inferred from direct assay
23275542 GOA
contributes to nuclear receptor activity IDA
IDA: Inferred from direct assay
34521881 GOA
enables nuclear receptor activity IDA
IDA: Inferred from direct assay
10395741 GOA
enables protein binding IPI
IPI: Inferred from physical interaction
9079689 GOA
enables protein heterodimerization activity IDA
IDA: Inferred from direct assay
28602820 GOA
enables sequence-specific double-stranded DNA binding IDA
IDA: Inferred from direct assay
28602820 GOA
enables transcription cis-regulatory region binding IDA
IDA: Inferred from direct assay
15681594 GOA
enables transcription coactivator binding IPI
IPI: Inferred from physical interaction
15641800 GOA
Biological Process GO Annotation Evidence References Source
involved in cAMP-mediated signaling IDA
IDA: Inferred from direct assay
17329248 GOA
involved in cellular response to 2,3,7,8-tetrachlorodibenzodioxine IDA
IDA: Inferred from direct assay
17329248 GOA
involved in cellular response to cAMP IDA
IDA: Inferred from direct assay
17329248 GOA
involved in cellular response to forskolin IDA
IDA: Inferred from direct assay
17329248 GOA
involved in cellular response to molecule of bacterial origin IDA
IDA: Inferred from direct assay
29454749 GOA
involved in negative regulation of T cell mediated immune response to tumor cell IDA
IDA: Inferred from direct assay
32818467 GOA
involved in negative regulation of inflammatory response IDA
IDA: Inferred from direct assay
29454749 GOA
involved in positive regulation of transcription by RNA polymerase II IDA
IDA: Inferred from direct assay
32818467 GOA
involved in regulation of B cell proliferation IDA
IDA: Inferred from direct assay
15681594 GOA
involved in regulation of DNA-templated transcription IDA
IDA: Inferred from direct assay
10395741 GOA
involved in regulation of adaptive immune response IDA
IDA: Inferred from direct assay
32818467 GOA
involved in regulation of gene expression IDA
IDA: Inferred from direct assay
15681594 GOA
involved in regulation of transcription by RNA polymerase II IDA
IDA: Inferred from direct assay
15681594 GOA
involved in response to toxic substance IDA
IDA: Inferred from direct assay
7961644 GOA
involved in response to xenobiotic stimulus IDA
IDA: Inferred from direct assay
7961644 GOA
Cellular Component GO Annotation Evidence References Source
located in cytoplasm IDA
IDA: Inferred from direct assay
15681594 GOA
located in cytosol IDA
IDA: Inferred from direct assay
17329248 GOA
part of nuclear aryl hydrocarbon receptor complex IDA
IDA: Inferred from direct assay
34521881 GOA
is active in nucleus IDA
IDA: Inferred from direct assay
28602820 GOA
located in nucleus IDA
IDA: Inferred from direct assay
10395741 GOA
part of protein-containing complex IMP
IMP: Inferred from mutant phenotype
15641800 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

AHR Protein Structure

HLH

HLH: Helix-loop-helix DNA-binding domain (37 - 78)

PAS

PAS: PAS fold (114 - 226)

PAS_3

PAS_3: PAS fold (300 - 382)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 848 a.a.
Protein Preferred Names Protein Names

aryl hydrocarbon receptor

  • AH-receptor

AHR Protein-protein interaction Information

Type
Protein Name Protein ID Interactor Interactor Species Interactor ID Detection Method References
Intra
AHR P35869 NCOA7 Homo sapiens Q8NI08
CoIP
10395741
Intra
AHR P35869 ARNT Homo sapiens P27540
Y2H
9704006
Intra
AHR P35869 ARNT Homo sapiens P27540
CoIP
10395741
Intra
AHR P35869 NCOR2 Homo sapiens Q9Y618
CoIP
10395741
Cross
AHR P35869 EBNA3 Epstein-Barr virus P12977
IF
16257957
Cross
AHR P35869 EBNA3 Epstein-Barr virus P12977
Pull Down
16257957
Cross
AHR P35869 EBNA3 Epstein-Barr virus P12977
Anti Tag CoIP
16257957
Cross: Cross-species interaction Intra: Intraspecies interaction

AHR Antibodies

Cat. No. Product Name Application Reactivity
HY-P80378 Aryl Hydrocarbon Receptor Antibody (YA610) WB, ICC/IF Human
HY-P82417 Aryl Hydrocarbon Receptor Antibody (YA2162) WB Human
HY-P82417A Aryl Hydrocarbon Receptor Antibody (YA2162)(PBS only) WB Human

Related Diseases

Diseases Alias
Retinitis Pigmentosa 85

  • RP85

  • Retinitis Pigmentosa, Type 85
Retinitis Pigmentosa

  • RP

  • Rod-Cone Dystrophy

  • Autosomal Recessive Retinitis Pigmentosa

  • Non-Syndromic Retinitis Pigmentosa

  • Pericentral Pigmentary Retinopathy

  • Pigmentary Retinopathy

  • Tapetoretinal Degeneration

  • Rcd

  • Retinitis Pigmentosa Autosomal Recessive

  • ARRP

  • Retinitis Pigmentosa, Autosomal Recessive

  • Retinitis Pigmentosa 1
Aryl Hydrocarbon Hydroxylase Inducibility

  • Ahh Inducibility

  • Ahhi
Eosinophilia-Myalgia Syndrome

  • Eosinophilia Myalgia Syndrome

  • Ems

  • L-Tryptophan Induced Ems

  • Severe Muscle Pain And Abnormally High Eosinophils

  • Syndrome With Inflammatory And Autoimmune Components That Affect The Skin, Fascia, Muscle, Nerve, Blood Vessels, Lung, And Heart
Breast Cancer

  • Breast Carcinoma

  • Male Breast Cancer

  • Breast Cancer, Familial

  • Malignant Neoplasm Of Breast

  • Breast Cancer, Susceptibility To

  • Breast Cancer, Early-Onset

  • Malignant Tumor Of Breast

  • Carcinoma Of Male Breast

  • Breast Cancer, Invasive Ductal

  • Breast Cancer, Protection Against

  • Breast Cancer, Somatic

  • Breast Cancer, Male

  • Breast Cancer, Lobular, Somatic

  • Breast Tumor

  • Mammary Cancer

  • Mammary Tumor

  • Malignant Neoplasm Of Male Breast

  • Mammary Carcinoma

  • Male Breast Carcinoma

  • Familial Cancer Of Breast

  • Invasive Ductal Breast Carcinoma

  • Breast Cancer Susceptibility

  • Breast Cancer, Male, Susceptibility To

  • Breast Cancer, Early-Onset, Susceptibility To

  • Malignant Tumor Of The Breast

  • Mammary Neoplasm

  • Primary Breast Cancer

  • Neoplasm Of Male Breast

  • Carcinoma Of Breast

  • Breast Cancer In Men

  • Familial Breast Cancer

  • Cancer Of Breast

  • BC

  • Breast Cancer Familial

  • Breast Cancer Familial Male

  • Breast Cancer, Familial Male

  • Breast Male Carcinoma

  • Breast Neoplasms

  • Breast Neoplasms, Male

  • Mammary Tumors

  • Mammary Carcinomas

  • Cancer, Breast

  • Cancer, Breast, Susceptibility

  • Invasive Breast Ductal Carcinoma

  • Breast Neoplasm

  • Susceptibility To Breast Cancer

  • Mammary Neoplasms

  • Animal Mammary Neoplasms

  • Primary Malignant Neoplasm Of Breast

  • Infiltrating Ductal Carcinoma Of Breast

  • Infiltrating Duct Carcinoma Of Unspecified Site

  • Infiltrating Ductular Carcinoma Of Unspecified Site

  • Invasive Breast Carcinoma Of No Special Type

  • Microinvasive Carcinoma Of Breast

  • Carcinoma With Apocrine Differentiation
Penis Agenesis

  • Micropenis

  • Agenesis Of The Penis

  • Penis Agenesia
Colon Adenocarcinoma

  • Adenocarcinoma Of Colon

  • Adenocarcinoma Of The Colon

  • Colonic Adenocarcinoma
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (11)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-109044 Tapinarof Agonist 99.95% Unkown
HY-A0083 Methacholine chloride Agonist ≥98.0% Yes
HY-N0178 Diosmin Agonist 98.62% Yes
HY-B0311 Carbidopa Modulator 99.84% Yes
HY-W017113 2-Mercaptobenzothiazole 99.85% Yes
HY-B0311A Carbidopa monohydrate Modulator 99.84% Yes
HY-B0678 Metaxalone 99.77% Unkown
HY-17357 Nepafenac Inhibitor 99.56% Unkown
HY-17479 Amfenac / Unkown
HY-A0083B Methacholine bromide Agonist / Unkown
HY-B0678R Metaxalone (Standard) / Unkown

Clinical Phase

Bioactive Molecules (11)
Cat. No. Product Name Effect
Purity Phase
HY-N0170 Indole-3-carbinol 99.16% Phase 3
HY-B2132 Tryptamine 99.89% Phase 3
HY-W013053 Dibenz[a,h]anthracene Inducer 98.0% Phase 3
HY-15001 Stemregenin 1 Antagonist 99.95% Phase 2
HY-16031B AFP464 dihydrochloride 99.45% Phase 2
HY-16031 AFP464 free base / Phase 2
HY-16031A AFP464 / Phase 2
HY-135829 BAY 2416964 Antagonist 99.59% Phase 1
HY-111449 BAY-218 Antagonist 99.78% Phase 1
HY-N0170R Indole-3-carbinol (Standard) 98.31% Phase 1
HY-136220 AHR antagonist 5 Antagonist 98.05% Phase 1

Pre-clinical Phase

Bioactive Molecules (170)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-12684 CH-223191 Antagonist 99.82% Unkown
HY-12028 PD98059 99.94% Unkown
HY-15484 Pifithrin-α hydrobromide 99.94% Unkown
HY-12451 FICZ Agonist 99.42% Unkown
HY-W028393 Indole-3-pyruvic acid Agonist 99.55% Unkown
HY-19317 ITE Agonist 99.27% Unkown
HY-102023 GNF351 Antagonist 99.87% Unkown
HY-W011910 Potassium 1H-indol-3-yl sulfate 99.95% Unkown
HY-W015273A trans-3-Indoleacrylic acid Inhibitor 99.77% Unkown
HY-114740 β-Naphthoflavone 99.86% Unkown
HY-W007355 Skatole 99.99% Unkown
HY-141609 IK-175 Inhibitor 99.89% Unkown
HY-122208 SGA360 Inhibitor 99.93% Unkown
HY-133677 Mono(2-ethyl-5-hydroxyhexyl) phthalate 99.03% Unkown
HY-103220 6,2',4'-Trimethoxyflavone Antagonist 98.02% Unkown
HY-W011338 Benzyl butyl phthalate Activator 97.0% Unkown
HY-134217 KYN-101 Inhibitor 98.03% Unkown
HY-119019 ASB14780 Inhibitor 99.58% Unkown
HY-B0845 Prochloraz 99.85% Unkown
HY-W014502 D-Kynurenine Agonist 99.94% Unkown
HY-W014075 1-Hydroxypyrene 99.38% Unkown
HY-103221 MeBIO 98.0% Unkown
HY-18619 YL-109 Modulator 98.91% Unkown
HY-132429S Potassium 1H-indol-3-yl sulfate-d5 99.77% Unkown
HY-112628 CAY10464 Antagonist 99.77% Unkown
HY-N1939 Icariside I 98.76% Unkown
HY-144339 AhR agonist 2 99.89% Unkown
HY-135750 VAF347 Agonist 99.75% Unkown
HY-12545 Brevetoxin-3 Activator 95.0% Unkown
HY-112629 PDM2 Antagonist 98.96% Unkown
HY-117532 PenCB Inducer 99.82% Unkown
HY-77278 25-Hydroxytachysterol3 Agonist 98.07% Unkown
HY-15001G Stemregenin 1 (GMP) Antagonist / Unkown
HY-N0914 Ajugol 99.80% Unkown
HY-111450 CB7993113 Antagonist 98.0% Unkown
HY-D0932 Sudan IV 98.0% Unkown
HY-G0006 Omeprazole sulfide 99.88% Unkown
HY-W014701 1,4-Dihydroxy-2-naphthoic acid 99.60% Unkown
HY-117102 ANI-7 Activator 99.01% Unkown
HY-G0007 Omeprazole sulfone Control 99.23% Unkown
HY-118438 10-Cl-BBQ Agonist 99.46% Unkown
HY-W718300 Indole-3-pyruvic acid-d5 96.31% Unkown
HY-W011910S Potassium 1H-indol-3-yl sulfate-d4 Activator 99.9% Unkown
HY-17663 KMR-206 98.86% Unkown
HY-W011338S Benzyl butyl phthalate-d4 98.38% Unkown
HY-N0586A Norisoboldine hydrochloride Agonist 99.72% Unkown
HY-124421 5F-203 Inducer 98.04% Unkown
HY-RS00483 AHR Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-B0973 Dibenzothiophene Inhibitor 99.92% Unkown
HY-112627 CAY 10465 Agonist 98.30% Unkown
HY-114682 Lenperone Antagonist 98.11% Unkown
HY-N4095 Brevifolincarboxylic acid Inhibitor 99.90% Unkown
HY-130256 β-NF-JQ1 Degrader 98.05% Unkown
HY-105791 Sulazepam 99.56% Unkown
HY-147128 PY109 Agonist 99.15% Unkown
HY-34505 1-Methyl-5-pyrazolecarboxylic acid 99.83% Unkown
HY-W012278 Benz[a]anthracene Ligand 99.90% Unkown
HY-111441 1,4-Chrysenequinone Activator 99.97% Unkown
HY-120377 CYP1A1 inhibitor 8a Inhibitor 98.00% Unkown
HY-124404 12(R)-HETE 99.90% Unkown
HY-125019 iJak-381 Inhibitor 99.86% Unkown
HY-135831 AHR antagonist 2 Antagonist 99.30% Unkown
HY-B0311AS Carbidopa-d3 monohydrate Modulator 98.53% Unkown
HY-W014075S 1-Hydroxypyrene-d9 99.95% Unkown
HY-W764758 3-OH-Kynurenamine dihydroiodide Activator 99.56% Unkown
HY-12028R PD98059 (Standard) 99.72% Unkown
HY-103222 DiMNF Modulator 98.46% Unkown
HY-103223 Phortress Inducer 98.19% Unkown
HY-N0586 Norisoboldine Agonist 99.93% Unkown
HY-W251708 AHR 10240 / Unkown
HY-114740R β-Naphthoflavone (Standard) 99.49% Unkown
HY-RS16533 Ahr Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-100242 Mivotilate Activator 99.58% Unkown
HY-104026CS L-Kynurenine-13C10 sulfate hemihydrate Agonist 99.90% Unkown
HY-118474 GW 610 Activator 99.78% Unkown
HY-118780 CHD-5 Antagonist 98.0% Unkown
HY-17357S Nepafenac-d5 Inhibitor 98.84% Unkown
HY-N10123 Indolokine A5 Agonist 98.0% Unkown
HY-N6264 26-Deoxyactein Inhibitor 99.76% Unkown
HY-W014502R D-Kynurenine (Standard) Agonist 99.99% Unkown
HY-W046846 Corannulene Agonist 97.31% Unkown
HY-W338764 AHR agonist 3 99.79% Unkown
HY-133677S Mono(2-ethyl-5-hydroxyhexyl) phthalate-d4 96.23% Unkown
HY-154825 20-Hydroxyvitamin D3 ≥98.0% Unkown
HY-W095381 N-Methylscatole Agonist 98.45% Unkown
HY-131340 LASSBio-1632 Inhibitor / Unkown
HY-136220A AHR antagonist 5 hemimaleate Antagonist / Unkown
HY-101745B Rocastine fumarate Inhibitor / Unkown
HY-101802 Fluzinamide / Unkown
HY-104026B L-Kynurenine sulfate Agonist / Unkown
HY-106487 Pridefine Inhibitor / Unkown
HY-111157 Dezinamide / Unkown
HY-114682A Lenperone hydrochloride Antagonist / Unkown
HY-116148 AHR-11797 / Unkown
HY-116638 AHR-5333 Inhibitor / Unkown
HY-116638A AHR-5333 mandelate Inhibitor / Unkown
HY-117774 AHR-2244 hydrochloride / Unkown
HY-118792 AHR activator 1 / Unkown
HY-119018 AHR-6293 Inhibitor / Unkown
HY-119960 AHR-10037 Inhibitor / Unkown
HY-120677 AHR-15010 Inhibitor / Unkown
HY-123432 AHR-13268D Inhibitor / Unkown
HY-123461 Sul-121 hydrochloride Inhibitor / Unkown
HY-124021 Benzyl 2-naphthyl ether 99.44% Unkown
HY-125926A (S)-2-Ketodoxapram / Unkown
HY-125926S 2-Ketodoxapram-d5 / Unkown
HY-129305 Tampramine fumarate Inhibitor / Unkown
HY-130269 β-Naphthoflavone-CH2-OH / Unkown
HY-130270 AhR Ligand-Linker Conjugates 1 / Unkown
HY-130842 β-Naphthoflavone-CH2-Br / Unkown
HY-132974 Aminoflavone / Unkown
HY-135671 AhR modulator-1 / Unkown
HY-135830 AHR antagonist 4 Antagonist / Unkown
HY-136876 AHR-12234 citrate / Unkown
HY-136891 AHR-16303B / Unkown
HY-139117 6,2′,4′-Trimethoxyflavone Antagonist / Unkown
HY-155505 AHR agonist 4 Agonist / Unkown
HY-156908 3-OH-Kynurenamine Activator / Unkown
HY-158167 AhR agonist 5 Agonist / Unkown
HY-158168 AhR agonist 6 Agonist / Unkown
HY-158169 AhR agonist 7 Agonist / Unkown
HY-161649 hCYP1B1-IN-2 Inhibitor / Unkown
HY-168033 AhR agonist 8 Agonist / Unkown
HY-169753 AHR-IN-1 Inhibitor / Unkown
HY-173393 LXRα agonist 1 Agonist / Unkown
HY-17479B Amfenac sodium / Unkown
HY-175785 X15695 98.45% Unkown
HY-176771 Tapinarof prodrug-1 / Unkown
HY-178053 AHR agonist 10 / Unkown
HY-181472 10(11)-Cl-BBQ / Unkown
HY-181629 ZSTK3744 / Unkown
HY-181629A ZSTK3744 hydrochloride / Unkown
HY-182495 Penisimplicissin Inhibitor / Unkown
HY-184554 ZY-MY-111 Inhibitor / Unkown
HY-19826 Isofistularin-3 / Unkown
HY-A0083C Methacholine iodide Agonist / Unkown
HY-B0311D Carbidopa hydrochloride Modulator / Unkown
HY-B0311S1 Carbidopa-d3-1 Modulator / Unkown
HY-B0678S Metaxalone-d3 98.0% Unkown
HY-B0678S1 Metaxalone-d6 / Unkown
HY-B0973S Dibenzothiophene-d8 Inhibitor / Unkown
HY-G0007S Omeprazole sulfone-d3 Control / Unkown
HY-G0007S1 Omeprazole sulfone-13C,d3 Control / Unkown
HY-N12537A (2R,3S)-PD-1/PD-L1-IN-38 / Unkown
HY-N16465 Cinnamtannin D1 Inhibitor / Unkown
HY-W716464 Prochloraz-d7 / Unkown
HY-101745 Rocastine Inhibitor / Unkown
HY-104026BS L-Kynurenine-13C10 sulfate Agonist / Unkown
HY-107063 AHR-1911 Activator 99.66% Unkown
HY-109044S Tapinarof-d5 Agonist / Unkown
HY-118910 AHR-14310C Antagonist / Unkown
HY-119991 AHR-9294 Inhibitor / Unkown
HY-125926S1 2-Ketodoxapram-d4 / Unkown
HY-128229 AHR antagonist 6 Antagonist / Unkown
HY-129247 Versicolorin A / Unkown
HY-130456 AHR 10718 Inhibitor / Unkown
HY-148637 Picoberin Agonist / Unkown
HY-163665 AHR antagonist 8 / Unkown
HY-167214 (+)-Ketodoxapram / Unkown
HY-170514 1,2,3,7,8,9-Hexachlorodibenzofuran Ligand / Unkown
HY-177563 AhR modulator-2 Activator / Unkown
HY-20888 3'-Methoxy-4'-nitroflavone / Unkown
HY-B0845R Prochloraz (Standard) / Unkown
HY-D0932S Sudan IV-d6 / Unkown
HY-N16435 Plumericin / Unkown
HY-RS22964 Ahr Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-U00010 Dazopride / Unkown
HY-W007355S2 Skatole-13C6 / Unkown
HY-W587465 9,10-Dichlorophenanthrene / Unkown
HY-W714200 Neburon / Unkown

Orthologs Information

Species Symbol Source ID
Canis familiaris AHR VGNC VGNC:54752
Rattus norvegicus AHR RGD RGD:2074
Mus musculus AHR MGD MGI:105043
Others AHR NCBI